Intimate Partner Violence and Mental Health: PTSD, Depression, Traumatic Brain Injury, and Barriers to Care — A Clinical Review

Intimate partner violence (IPV) — defined as physical violence, sexual violence, stalking, or psychological aggression by a current or former intimate partner — is among the most prevalent and clinically consequential forms of interpersonal trauma worldwide. The World Health Organization estimates that approximately 27% of women aged 15–49 globally have experienced physical and/or sexual IPV in their lifetime, a figure that has remained stubbornly stable across decades of public health intervention. In the United States, the National Intimate Partner and Sexual Violence Survey (NISVS) conducted by the CDC reports that approximately 1 in 4 women (25.1%) and 1 in 10 men (10.9%) have experienced contact sexual violence, physical violence, and/or stalking by an intimate partner with IPV-related impact during their lifetime.

IPV is not merely a social or legal problem — it is a major driver of psychiatric morbidity. Survivors of IPV exhibit elevated rates of posttraumatic stress disorder (PTSD), major depressive disorder (MDD), substance use disorders (SUDs), anxiety disorders, and suicidality at rates that substantially exceed those observed in the general population and even many other trauma-exposed populations. Adding further complexity, IPV frequently involves repetitive head and neck trauma, producing traumatic brain injuries (TBI) that are underdiagnosed, poorly understood, and capable of compounding psychiatric symptomatology in ways that confound standard diagnostic assessment.

This article provides a clinically detailed review of the psychiatric sequelae of IPV, the neurobiological mechanisms through which chronic interpersonal trauma alters brain structure and function, the diagnostic challenges inherent in this population, evidence-based treatment approaches with outcome data, and the systemic and individual barriers that prevent survivors from accessing effective care. The goal is to equip clinicians with the depth of understanding necessary to provide competent, trauma-informed assessment and treatment for IPV survivors.

The epidemiology of IPV-related mental health consequences reveals a pattern of extraordinarily high comorbidity. Meta-analytic data consistently demonstrate that IPV survivors exhibit psychiatric disorder prevalence rates far exceeding population base rates:

• PTSD: Meta-analyses estimate PTSD prevalence among IPV survivors at 31–84%, with the wide range reflecting differences in sample composition (shelter-based vs. community-based), measurement instruments, and whether the sample includes individuals who have recently left versus those still in abusive relationships. A landmark meta-analysis by Golding (1999), pooling 11 studies, found a weighted mean PTSD prevalence of 63.8% among battered women — roughly 10 times the general population lifetime prevalence of approximately 6.1% (DSM-5-TR).
• Major Depressive Disorder: The same Golding meta-analysis found a weighted mean depression prevalence of 47.6% among IPV survivors, compared to a 12-month prevalence of approximately 7% in the general U.S. adult population (NIMH). Subsequent studies have consistently replicated this finding, with depression prevalence in IPV samples typically ranging from 35–70%.
• Substance Use Disorders: Alcohol and drug use disorders affect an estimated 18.5–44.0% of IPV survivors, with SUDs often serving dual functions as coping mechanisms for trauma-related distress and as consequences of disinhibited behavior in chaotic relational environments.
• Suicidality: IPV is among the strongest predictors of suicidal ideation and suicide attempts. Studies estimate that 17.9–23.0% of IPV survivors report having attempted suicide, compared to approximately 4.6% in the general population. The Golding (1999) meta-analysis found a weighted mean suicidality prevalence of 17.9%.
• Traumatic Brain Injury: Emerging research, particularly the work of Valera and Berenbaum (2003), estimates that 35–92% of IPV survivors have sustained at least one TBI, predominantly from blows to the head, strangulation, or being slammed against surfaces. The vast majority of these injuries go undiagnosed.

Comorbidity is the rule, not the exception. PTSD-MDD comorbidity in IPV populations is estimated at 48–75%, substantially higher than the approximately 50% PTSD-MDD co-occurrence observed in general trauma samples. The addition of TBI creates a triad of overlapping symptomatology — cognitive impairment, emotional dysregulation, somatic complaints — that presents extraordinary diagnostic challenges.

Key risk factors for more severe psychiatric outcomes following IPV include: greater severity, frequency, and duration of abuse; sexual violence in addition to physical violence; childhood trauma history (creating cumulative or compounding trauma burden); lower socioeconomic status; lack of social support; and immigration status or language barriers that increase isolation.

The neurobiological consequences of IPV involve the convergence of at least two distinct but interacting pathophysiological processes: (1) chronic stress-mediated neuroplastic changes characteristic of PTSD and complex trauma, and (2) structural brain injury from repetitive head trauma and hypoxic-anoxic injury secondary to strangulation.

HPA Axis Dysregulation and Glucocorticoid Signaling

Chronic exposure to threat — the defining feature of life with an abusive partner — produces sustained activation of the hypothalamic-pituitary-adrenal (HPA) axis. Initially, this results in hypercortisolism; with prolonged exposure, many trauma survivors develop hypocortisolism (blunted cortisol reactivity), a pattern frequently observed in PTSD and thought to reflect downregulation of glucocorticoid receptors in the hippocampus and prefrontal cortex. This shift has direct clinical implications: hypocortisolism is associated with enhanced fear conditioning, impaired fear extinction, and reduced capacity for contextual discrimination — core features of PTSD symptomatology. The FKBP5 gene, which encodes a co-chaperone protein that modulates glucocorticoid receptor sensitivity, has been identified as a critical moderator. Specific polymorphisms in FKBP5 (particularly rs1360780) interact with childhood abuse history to predict PTSD risk, through epigenetic mechanisms involving demethylation of glucocorticoid response elements. While most of this research derives from childhood maltreatment samples, emerging evidence suggests similar gene-environment interactions operate in adult IPV populations.

Amygdala-Prefrontal Circuitry

Neuroimaging research in trauma-exposed populations consistently demonstrates amygdala hyperreactivity paired with hypoactivation of the ventromedial prefrontal cortex (vmPFC) and dorsolateral prefrontal cortex (dlPFC). This pattern reflects impaired top-down regulation of fear responses and is considered a central neural signature of PTSD. In IPV populations specifically, studies have documented reduced gray matter volume in the prefrontal cortex, with the degree of reduction correlating with abuse severity and duration. The anterior cingulate cortex (ACC), which serves as a critical interface between prefrontal regulatory regions and limbic structures, shows both structural reduction and functional underactivation in IPV-related PTSD.

Hippocampal Volume Reduction

The hippocampus, essential for contextual memory processing and fear extinction, is particularly vulnerable to glucocorticoid-mediated neurotoxicity. Meta-analytic data demonstrate hippocampal volume reductions of approximately 5–12% in PTSD populations, with bilateral reduction more common in samples with chronic or repeated trauma — precisely the exposure pattern characteristic of IPV. Reduced hippocampal volume impairs the ability to contextualize fear memories, contributing to generalized hypervigilance, re-experiencing symptoms, and difficulty distinguishing safe from unsafe environments.

Noradrenergic and Serotonergic Dysregulation

Chronic interpersonal trauma drives upregulation of the locus coeruleus-norepinephrine (LC-NE) system, producing tonic hyperarousal, exaggerated startle, and sleep disturbance. The serotonergic system, originating in the dorsal raphe nuclei and projecting broadly to cortical and limbic structures, is simultaneously disrupted — contributing to the mood, appetite, and sleep disturbances that characterize comorbid depression. Polymorphisms in the serotonin transporter gene (SLC6A4), particularly the short allele of the 5-HTTLPR promoter region, have been associated with increased vulnerability to depression following interpersonal violence, though the effect size is modest and gene-environment interaction findings in this area have not always replicated.

Strangulation and Hypoxic-Anoxic Brain Injury

An underappreciated mechanism of brain injury in IPV is non-fatal strangulation, which occurs in an estimated 50–68% of abusive relationships. Strangulation produces transient cerebral hypoxia-anoxia, even when the victim does not lose consciousness. Repeated episodes can cause cumulative injury to brain regions with the highest metabolic demand — the hippocampus, basal ganglia, and watershed cortical zones. This mechanism is distinct from direct mechanical TBI and may explain cognitive deficits (memory impairment, executive dysfunction, processing speed reduction) observed in IPV survivors who do not report direct head impact.

Repetitive Mild TBI and Chronic Traumatic Encephalopathy Parallels

The pattern of repetitive mild TBI (rmTBI) in IPV has drawn comparisons to sports-related concussion and chronic traumatic encephalopathy (CTE). While CTE research in IPV populations is in its infancy, neuropathological parallels are being explored. Repetitive head injury produces neuroinflammation, axonal shearing, microglial activation, and tau protein accumulation. In IPV contexts, the combination of rmTBI and chronic psychological stress may be synergistic — neuroinflammation from injury amplifies stress-mediated neurodegeneration, and stress hormones impair post-injury neuroplastic recovery.

Accurate psychiatric assessment in IPV survivors is complicated by substantial symptom overlap between PTSD, MDD, and TBI, and by the fact that the ICD-11 category of Complex PTSD (CPTSD) — which may better capture the clinical picture than standard PTSD — is not yet formally recognized in the DSM-5-TR.

PTSD vs. Complex PTSD

DSM-5-TR defines PTSD by four symptom clusters: intrusion, avoidance, negative alterations in cognition and mood, and arousal/reactivity disturbances. ICD-11 distinguishes PTSD from CPTSD, which adds three additional "disturbances in self-organization" (DSO) domains: affect dysregulation, negative self-concept, and disturbances in relationships. IPV survivors frequently present with the full CPTSD phenotype — emotional flashbacks, chronic shame, identity disturbance, and relational difficulties — that may be inadequately captured by a standard PTSD diagnosis. The International Trauma Questionnaire (ITQ) has demonstrated good psychometric properties for distinguishing PTSD from CPTSD, with studies in IPV populations showing that 36–50% of trauma-exposed individuals with post-traumatic pathology meet CPTSD rather than PTSD criteria.

Depression-PTSD Overlap

DSM-5-TR Criterion D for PTSD (negative alterations in cognitions and mood) shares substantial content with MDD diagnostic criteria: diminished interest, feelings of detachment, restricted positive affect, and negative beliefs about self and world. Differential diagnosis requires careful assessment of whether depressive symptoms are trauma-specific (linked to the index trauma and its meaning) or represent an independent depressive episode. Comorbid MDD is diagnosed when depressive symptoms extend beyond trauma-related cognitions to include vegetative features (appetite and weight change, psychomotor retardation, fatigue) and pervasive anhedonia not exclusively tied to trauma reminders. In clinical practice, the distinction is often blurred, and both conditions frequently require concurrent treatment.

TBI Confounds

The cognitive and emotional sequelae of TBI — including impaired concentration, memory deficits, irritability, emotional lability, headaches, sleep disturbance, and executive dysfunction — overlap extensively with both PTSD and MDD. A survivor presenting with difficulty concentrating, sleep disruption, irritability, and memory problems could meet criteria for PTSD Cluster E (arousal), MDD cognitive symptoms, or postconcussive syndrome — or all three simultaneously. Critically, TBI may impair the cognitive capacities needed for effective trauma-focused psychotherapy, including the ability to sustain attention during prolonged exposure, encode new safety-learning during cognitive processing therapy (CPT), and consolidate treatment gains between sessions.

Key Differential Diagnosis Pitfalls

• Misattributing TBI symptoms to "treatment resistance": IPV survivors with undiagnosed TBI may fail to respond to standard PTSD treatments, leading clinicians to escalate pharmacotherapy or conclude that the patient is not engaging with treatment, when the actual barrier is neurocognitive impairment.
• Under-recognition of strangulation history: Standard psychiatric intake does not routinely inquire about strangulation. Because strangulation may not leave visible marks and survivors may not recognize it as an injury event, clinicians must ask directly: "Has your partner ever put hands around your neck, choked you, or cut off your air or blood flow?"
• Misdiagnosing CPTSD as personality disorder: The affect dysregulation, identity disturbance, and interpersonal difficulties characteristic of CPTSD overlap with borderline personality disorder (BPD) criteria. Careful trauma history assessment is essential to avoid pathologizing trauma adaptations as characterological disorder. Research by Cloitre and colleagues has demonstrated that CPTSD and BPD are distinguishable constructs with different latent profiles, though comorbidity does occur.

The psychotherapy evidence base for IPV-related PTSD draws heavily from the broader trauma-focused therapy literature, with a growing number of trials conducted specifically in IPV populations.

Cognitive Processing Therapy (CPT)

CPT, developed by Patricia Resick, has the strongest evidence base specifically in IPV populations. The landmark Resick et al. (2002) randomized controlled trial compared CPT, Prolonged Exposure (PE), and a minimal attention control in female sexual assault survivors and demonstrated large effect sizes (Cohen's d = 1.5–1.8) for PTSD symptom reduction. In IPV-specific samples, CPT has demonstrated PTSD remission rates of approximately 40–60% and clinically significant symptom reduction in an additional 20–30% of participants. CPT's cognitive restructuring component — which targets trauma-related stuck points about safety, trust, power, esteem, and intimacy — is particularly well-suited to IPV, where distorted beliefs about self-blame, learned helplessness, and relational danger are core features of the clinical presentation.

Prolonged Exposure (PE)

PE, developed by Edna Foa, involves repeated, systematic engagement with trauma memories (imaginal exposure) and avoided situations (in vivo exposure) to promote habituation and emotional processing. PE has demonstrated large effect sizes for PTSD across trauma types, with PTSD remission rates of approximately 41–53% in intent-to-treat analyses. However, PE presents specific challenges in IPV populations: the in vivo exposure hierarchy may include situations (e.g., being alone, leaving the house, interpersonal conflict) that carry genuine safety risks for individuals still in contact with an abusive partner. Additionally, dropout rates in PE trials have been higher than in CPT trials in some comparative studies, with rates ranging from 20–38% depending on the sample.

Head-to-Head Comparison: CPT vs. PE

The Resick et al. (2012) dismantling trial and subsequent comparative effectiveness studies have generally found equivalent efficacy between CPT and PE for PTSD symptom reduction, consistent with the broader finding that evidence-based trauma therapies produce similar outcomes. However, some IPV-specific studies suggest that CPT may have a modest advantage in reducing comorbid depression and guilt, while PE may produce faster symptom reduction in the early sessions. A pragmatic consideration is that CPT may be more feasible in IPV populations because it does not require prolonged imaginal exposure — a component that some survivors find intolerable and that contributes to dropout.

EMDR (Eye Movement Desensitization and Reprocessing)

EMDR has demonstrated efficacy for PTSD in multiple meta-analyses, with effect sizes comparable to CPT and PE. In IPV-specific populations, a smaller evidence base exists, but available RCTs suggest PTSD response rates of 60–77% and significant reductions in depression. The NICE and WHO clinical guidelines include EMDR as a first-line recommendation for PTSD alongside trauma-focused CBT approaches.

Trauma-Focused Interventions for Complex PTSD

For CPTSD presentations — common in IPV — phase-based treatment models are widely recommended, beginning with stabilization and emotion regulation skills before progressing to trauma memory processing. The Skills Training in Affective and Interpersonal Regulation followed by Modified PE (STAIR/MPE), developed by Marylene Cloitre, demonstrated superiority over supportive counseling followed by MPE in a three-arm RCT (Cloitre et al., 2010), particularly for the DSO domains of affect dysregulation and interpersonal problems, with effect sizes of d = 0.7–1.0 for PTSD symptoms and significant improvements in emotion regulation capacities.

Number Needed to Treat (NNT)

Across evidence-based trauma-focused therapies, the NNT for PTSD remission (compared to waitlist or treatment-as-usual controls) is approximately NNT = 3–4, making these among the most effective treatments in all of psychiatry. Compared to active control conditions (supportive counseling, present-centered therapy), the NNT rises to approximately NNT = 6–8, reflecting the fact that non-specific therapeutic factors also produce meaningful improvement in some patients.

Pharmacological treatment in IPV-related psychiatric conditions serves primarily an adjunctive role, augmenting psychotherapy rather than replacing it. The evidence for pharmacotherapy as monotherapy for PTSD is substantially weaker than for psychotherapy.

SSRIs and SNRIs

Sertraline and paroxetine are the only FDA-approved medications for PTSD, with response rates in pivotal trials of approximately 53–60% versus 32–38% for placebo (NNT ≈ 4–5 versus placebo for response). However, PTSD remission rates with SSRIs are considerably lower — approximately 20–30% — and effect sizes are modest (Cohen's d = 0.3–0.5), substantially smaller than those achieved with trauma-focused psychotherapy. The VA/DoD Clinical Practice Guidelines (2023) and the APA guideline (2017) both position psychotherapy as the preferred first-line treatment, with pharmacotherapy recommended when psychotherapy is unavailable, declined, or insufficiently effective.

For comorbid MDD, SSRIs and SNRIs serve dual purposes, addressing both PTSD and depressive symptoms. Venlafaxine extended-release has demonstrated efficacy for PTSD comparable to SSRIs, with the additional advantage of noradrenergic reuptake inhibition that may address hyperarousal symptoms more effectively.

Prazosin for Trauma-Related Nightmares

Prazosin, an alpha-1 adrenergic antagonist, was initially shown to be effective for trauma-related nightmares and sleep disturbance in the Raskind et al. (2003) RCT and subsequent positive trials. However, the large, multi-site PACT trial (Raskind et al., 2018) — a VA-funded study of 304 veterans — found no significant difference between prazosin and placebo, creating clinical equipoise. Current guidelines suggest prazosin may still be considered on an individual basis, recognizing that the discrepancy between earlier and later trials may reflect differences in dosing, populations, and concurrent alcohol use.

Pharmacotherapy for IPV-Related TBI

No pharmacological agents are specifically approved for IPV-related TBI. Off-label use of methylphenidate and amantadine for post-TBI cognitive deficits, and melatonin/trazodone for sleep disturbance, is common in TBI populations but has not been studied specifically in IPV contexts. Clinicians should be aware that TBI-related disruption of neurotransmitter systems — particularly dopaminergic and cholinergic pathways — may alter responses to standard psychotropic medications, potentially increasing sensitivity to sedating side effects and impairing tolerability of anticholinergic medications.

Medications to Avoid or Use Cautiously

• Benzodiazepines: Contraindicated as a treatment for PTSD. Meta-analytic evidence shows no benefit for core PTSD symptoms, with evidence of harm including impaired fear extinction, increased risk of substance dependence, and worsened long-term PTSD outcomes. The VA/DoD guideline strongly recommends against their use in PTSD.
• Atypical antipsychotics: Limited evidence for PTSD augmentation. The large Krystal et al. (2011) VA trial found risperidone no better than placebo for PTSD augmentation, despite earlier positive small trials. Metabolic side effects further limit their utility.

TBI in the context of IPV has been described as a "hidden epidemic" due to its extraordinary prevalence combined with its near-total absence from routine clinical screening. The research program of Eve Valera and colleagues at Harvard has been instrumental in characterizing this problem.

Prevalence and Mechanism

Valera and Berenbaum (2003) found that 74% of IPV survivors in their sample had sustained at least one TBI from partner violence, with 51% reporting multiple TBIs. Mechanisms include direct blows to the head and face, being thrown into walls or furniture, being shaken, and non-fatal strangulation. Strangulation is particularly concerning because it can produce hypoxic brain injury without any external evidence of head trauma, and survivors may not associate a brief choking episode with brain injury.

Neuroimaging Findings

Valera et al. (2019) published neuroimaging data using diffusion tensor imaging (DTI) demonstrating white matter abnormalities in IPV survivors with TBI history, even in the absence of abnormalities on conventional structural MRI. Fractional anisotropy (FA) reductions were observed in the corona radiata, superior longitudinal fasciculus, and corpus callosum — tracts critical for interhemispheric communication and frontoparietal network integrity. These findings parallel those seen in sports-related concussion research and suggest that standard clinical neuroimaging (CT, conventional MRI) is insufficient to detect the microstructural damage produced by repetitive mild TBI in IPV.

Cognitive and Functional Consequences

IPV-related TBI has been associated with deficits in memory encoding and retrieval, processing speed, executive functioning (planning, cognitive flexibility, inhibition), and sustained attention. These deficits have direct implications for survivors' ability to navigate safety planning, legal proceedings, parenting, employment, and engagement in psychotherapy. Critically, cognitive deficits may be misattributed to depression, PTSD, substance use, or low intelligence — each a misattribution that can lead to inappropriate treatment and further marginalization.

Screening Recommendations

The HELPS Brain Injury Screening Tool and the Ohio State University TBI Identification Method (OSU TBI-ID) have been adapted for use in IPV populations. Routine screening should include questions about: head injuries from any cause, loss of consciousness, being "dazed" or "seeing stars" after a blow, strangulation or choking, and post-injury symptoms including headaches, dizziness, memory problems, and sensitivity to light/noise. Any affirmative response should trigger more detailed neuropsychological or neurocognitive evaluation.

Despite the severity of mental health consequences, IPV survivors face a constellation of barriers to accessing and benefiting from psychiatric treatment. These barriers operate at structural, systemic, clinician, and individual levels.

Structural and Systemic Barriers

• Financial dependence and insurance: Economic abuse — a form of IPV in which the abuser controls financial resources — affects an estimated 94–99% of IPV survivors and directly limits the ability to pay for treatment, maintain insurance, or access transportation to appointments.
• Fragmented service systems: Mental health services, domestic violence advocacy, legal aid, child welfare, and housing assistance typically operate in separate systems with poor coordination. Survivors must navigate multiple agencies, each with its own eligibility criteria, waitlists, and documentation requirements — a process that is cognitively demanding and retraumatizing.
• Shelter and safety constraints: Emergency shelter stays are typically limited to 30–90 days, a timeframe wholly insufficient for evidence-based trauma treatment (CPT and PE typically require 12–17 sessions over 8–16 weeks). The instability of shelter environments — shared living spaces, frequent transitions, ongoing crisis management — is antithetical to the predictability and safety needed for effective psychotherapy.
• Immigration-related fear: For undocumented survivors, fear of deportation represents a powerful deterrent to help-seeking. Abusers frequently weaponize immigration status, threatening to report partners to immigration authorities — a tactic so common it has been termed "immigration-related abuse."

Clinician-Level Barriers

• Inadequate training: Surveys of mental health professionals consistently reveal insufficient training in IPV assessment and intervention. A study by Warshaw et al. (2013) found that most mental health training programs provide fewer than 2 hours of didactic content on IPV, and fewer than 25% of clinicians report feeling competent to address IPV in their practice.
• Failure to screen: Despite recommendations from USPSTF (B recommendation for IPV screening in women of reproductive age), screening rates in mental health settings remain low. Clinicians cite discomfort, time constraints, and uncertainty about how to respond to positive screens.
• Misapplication of couples therapy: Conjoint therapy is contraindicated when active IPV is present, as it can escalate danger and silences the victimized partner. However, clinicians who fail to assess for IPV may inadvertently refer couples to conjoint treatment, potentially with life-threatening consequences.

Individual-Level Barriers

• Shame and self-blame: Internalized blame — reinforced by societal narratives about "why she stays" — produces shame that deters disclosure and help-seeking. These cognitions are precisely the "stuck points" targeted by CPT.
• Ongoing contact with the abuser: Shared custody, financial entanglement, and emotional attachment (often involving trauma bonding) mean that many survivors are not in a post-trauma state — they are experiencing ongoing or intermittently recurring trauma, which fundamentally complicates treatment planning.
• Cognitive impairment from TBI: As described above, TBI-related executive dysfunction may impair the survivor's ability to organize help-seeking behavior, follow through on referrals, remember appointment times, and process therapeutic material.

Understanding what predicts good versus poor outcomes in IPV-related psychiatric conditions enables clinicians to tailor treatment intensity and modality appropriately.

Predictors of Better Outcomes

• Physical safety: The single most powerful predictor of psychiatric improvement is cessation of violence exposure. Studies consistently show that PTSD and depression symptom trajectories improve significantly once the survivor has achieved physical separation from the abuser. However, separation is itself a period of elevated danger — the highest risk of lethal violence occurs in the period immediately following departure.
• Social support: Perceived social support, particularly from family and peers, is one of the strongest protective factors against PTSD chronicity, with meta-analytic effect sizes of r = -0.28 to -0.40 for the association between social support and PTSD severity.
• Early treatment engagement: Shorter duration between trauma cessation and treatment initiation predicts better psychotherapy outcomes. Chronic PTSD (duration > 3 months post-exposure) is more treatment-resistant than acute PTSD, though still responsive to evidence-based approaches.
• Absence of TBI: Intact neurocognitive functioning allows fuller engagement with the cognitive demands of trauma-focused psychotherapy.

Predictors of Poorer Outcomes

• Cumulative trauma burden: Childhood abuse history combined with adult IPV (polyvictimization) is associated with more severe, treatment-resistant PTSD and greater prevalence of CPTSD presentations. The ACE (Adverse Childhood Experiences) study demonstrated a dose-response relationship between cumulative trauma exposure and psychiatric morbidity.
• Comorbid substance use: Active SUDs reduce treatment engagement and response. Integrated treatment models addressing PTSD and SUD simultaneously (e.g., Seeking Safety, developed by Lisa Najavits) are preferable to sequential treatment, though evidence for the superiority of integrated approaches remains mixed.
• Comorbid TBI: Unaddressed cognitive deficits impair psychotherapy engagement. Cognitive rehabilitation prior to or concurrent with trauma-focused therapy may be necessary but is rarely available in community settings.
• Ongoing abuse or coercive control: Survivors who remain in abusive relationships show smaller and less durable treatment gains, though this should never be used to withhold treatment — psychotherapy can still reduce symptom burden and support safety planning even in the context of ongoing risk.
• Dissociation: High levels of peritraumatic and trait dissociation predict slower PTSD treatment response, particularly in PE, where emotional engagement with the trauma memory is the putative mechanism of change. Severely dissociative patients may require stabilization-focused approaches before trauma processing.

IPV occurs across all demographic groups, but its mental health consequences and treatment access are shaped by intersecting social identities and structural inequities.

LGBTQ+ Survivors

IPV prevalence in LGBTQ+ relationships is at least as high as in heterosexual relationships, with some studies suggesting higher rates — the NISVS found that 43.8% of lesbian women, 61.1% of bisexual women, 26.0% of gay men, and 37.3% of bisexual men report IPV in their lifetime. LGBTQ+ survivors face unique barriers including: fear of outing by the abuser, heteronormative assumptions in screening and services, and a smaller domestic violence service infrastructure designed for LGBTQ+ individuals. Minority stress — the chronic stress of living in a stigmatizing society — compounds IPV-related psychiatric consequences.

Black, Indigenous, and People of Color (BIPOC) Survivors

BIPOC IPV survivors navigate IPV within the context of systemic racism, intergenerational trauma, and justified distrust of systems (law enforcement, child welfare, mental health) that have historically been instruments of harm. The NISVS reports that American Indian/Alaska Native women experience IPV at rates approximately 1.5–2 times higher than the national average. Cultural factors influencing help-seeking behavior, mistrust of predominantly white clinical workforces, and the scarcity of culturally responsive trauma treatments represent significant barriers.

Male Survivors

Male IPV survivors are significantly underrecognized. Barriers include societal gender role expectations that equate victimhood with weakness, a domestic violence service infrastructure oriented primarily toward female survivors, and screening instruments that may not capture patterns of victimization experienced by men. Research suggests that male survivors may present with different symptom profiles, with externalizing behaviors (anger, substance use, risk-taking) potentially more prominent than the internalizing presentations (depression, anxiety) more common in female survivors.

Survivors with Disabilities

People with disabilities experience IPV at rates 1.5–3 times higher than people without disabilities, and may face unique forms of abuse including withholding of medications, destruction of assistive devices, and exploitation of physical or cognitive vulnerability. Pre-existing cognitive disability combined with IPV-related TBI can create severe compounding effects on functional capacity.

Despite significant advances, major gaps remain in the evidence base for IPV-related mental health conditions.

Active Research Areas

• IPV-related TBI biomarkers: Research is underway exploring blood-based biomarkers (serum neurofilament light chain, GFAP, tau) for detecting TBI in IPV survivors, potentially enabling objective diagnosis when neuroimaging is insensitive or unavailable. This work is in early stages, with promising but preliminary findings from studies led by Valera and colleagues.
• Adapted psychotherapies for TBI-affected survivors: Researchers are testing modifications to evidence-based trauma therapies — including shortened sessions, memory aids, repetition of key content, and integration of cognitive rehabilitation — to accommodate the neurocognitive impairments associated with IPV-related TBI. No large RCTs have yet been published in this area.
• Technology-assisted interventions: Telehealth delivery of CPT and PE has been shown to be non-inferior to in-person delivery in general trauma populations. For IPV survivors facing transportation, childcare, and safety barriers, telehealth represents a potentially transformative modality — but requires careful safety planning (e.g., ensuring the abuser cannot overhear sessions).
• Neuroinflammatory mechanisms: The intersection of psychological stress and brain injury in IPV is generating interest in neuroinflammatory pathways (microglial activation, pro-inflammatory cytokines including IL-6 and TNF-alpha) as shared mechanisms driving PTSD, depression, and neurocognitive decline. Anti-inflammatory interventions (e.g., low-dose minocycline, omega-3 fatty acids) are being explored as potential adjunctive treatments, though evidence remains preclinical and very early-phase.
• Epigenetic studies: Research is examining whether IPV exposure produces epigenetic modifications (particularly DNA methylation changes in stress-related genes including NR3C1, FKBP5, and BDNF) that could serve as biomarkers of exposure or predictors of treatment response. This field is nascent but holds promise for understanding individual differences in resilience versus vulnerability.

Key Limitations

• Exclusion of active IPV from clinical trials: Most psychotherapy RCTs for PTSD exclude participants who are currently experiencing IPV or are in active danger, limiting the generalizability of findings to the population most in need of treatment.
• Underrepresentation of men, LGBTQ+ individuals, and BIPOC populations in clinical trials limits the applicability of current evidence to these groups.
• No TBI-specific treatment guidelines for IPV: While TBI clinical pathways exist in sports medicine and military medicine, no clinical guidelines address the detection and management of TBI in the IPV context.
• Lack of longitudinal outcome data: Most treatment studies follow participants for 3–12 months. The long-term trajectories of IPV-related PTSD, depression, and TBI — particularly regarding neurodegeneration and dementia risk associated with repetitive mild TBI — remain poorly characterized.

Optimal care for IPV survivors requires integration across multiple clinical domains, a principle that is widely endorsed but rarely implemented.

Screening

Universal screening for IPV should be implemented in all mental health settings using validated instruments such as the HITS (Hurt, Insult, Threaten, Scream) tool or the STAT (Slapped, Threatened, and Throw) screening instrument. The USPSTF (2018) issued a B recommendation for IPV screening in women of reproductive age, finding adequate evidence that screening tools accurately detect IPV and that interventions reduce IPV and improve outcomes. Any positive screen should trigger assessment for TBI history and suicidality.

Integrated Assessment

Assessment should systematically evaluate: (1) current safety and lethality risk (using structured tools such as the Danger Assessment by Jacquelyn Campbell), (2) PTSD and CPTSD symptomatology, (3) comorbid MDD, SUD, and suicidality, (4) TBI and strangulation history, (5) neurocognitive functioning (brief screening with the Montreal Cognitive Assessment [MoCA] or similar instrument), and (6) social determinants including housing, financial resources, legal involvement, and childcare needs.

Stepped-Care Treatment Model

A stepped-care approach is recommended:

• Step 1 — Safety and stabilization: Collaborative safety planning, connection to advocacy services, stabilization of acute psychiatric symptoms (crisis management, medication if needed), and addressing basic needs (housing, food, legal protection).
• Step 2 — Emotion regulation and coping skills: For survivors with CPTSD presentations or active instability, skills-based interventions (STAIR, DBT-informed skills training, Seeking Safety for comorbid PTSD-SUD) before progressing to trauma processing.
• Step 3 — Trauma-focused therapy: CPT, PE, or EMDR once safety is established and the survivor demonstrates adequate emotion regulation and cognitive capacity for trauma processing.
• Step 4 — Maintenance and relapse prevention: Ongoing monitoring, booster sessions as needed, continued advocacy support, and attention to long-term consequences of TBI.

Collaboration with Non-Clinical Services

Effective care requires active collaboration between mental health clinicians and domestic violence advocates, legal advocates, housing services, and child welfare. Clinicians should familiarize themselves with local DV resources, understand mandatory reporting requirements in their jurisdiction, and develop referral pathways that are warm (i.e., direct handoff) rather than passive (i.e., providing a phone number).